SCHEMBL7124977

SCHEMBL7124977

CC(=O)Nc1ccc(Oc2ccc(C(=O)N[C@@H]3C[C@H]4CC[C@@H]3N4)cc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 4/20 0.41
MMP9 P14780 4/20 0.41
MMP7 P09237 2/20 0.41
MMP13 P45452 1/20 0.41
HTT P42858 3/20 0.40
MAPT P10636 2/20 0.40
ABL1 P00519 1/20 0.40
RIN1 Q13671 1/20 0.40
MTNR1A P48039 1/20 0.40
MTNR1B P49286 1/20 0.40
MMP1 P03956 1/20 0.40
MMP3 P08254 1/20 0.40
MMP8 P22894 1/20 0.40
MMP14 P50281 1/20 0.40
CACNA1B Q00975 1/20 0.39
APBA1 Q02410 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MEN1 O00255 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7116944 0.89 HPGD (0.46) MMP2MMP9MMP7MMP13HTT
SCHEMBL7124006 0.88 MAPT (0.40) MMP2MMP9MMP7MMP13MAPT
SCHEMBL7126711 0.88 HRH3 (0.47) HTTMAPTSMN1; SMN2ALDH1A1KMT2A
SCHEMBL7123882 0.87 MMP2 (0.35) MMP2MMP9MMP7MMP13HTT
SCHEMBL7117116 0.87 CHRNA7 (0.42) HTTMAPTABL1RIN1CACNA1B
SCHEMBL7115196 0.86 MMP2 (0.43) MMP2MMP9MMP7MMP13HTT
SCHEMBL7127599 0.86 NAAA (0.49) MMP2MMP9MMP7MMP13
SCHEMBL7122675 0.86 MMP2 (0.34) MMP2MMP9MMP7MMP13HTT
SCHEMBL7123375 0.86 MEN1 (0.40) MMP2MMP9MMP7MMP13ABL1
SCHEMBL7125166 0.85 KMT2A (0.40) MMP2MMP9MMP7MMP13HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-04-10 US claimed
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease CYP7B1, UGT2B7, CYP1B1 MMP2 3731/4885MMP9 3029/4885MMP7 2061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.